News & Updates

While diabetes is a risk factor for cataract, glucose-lowering medications appear to have a protective effect on the risks of open-angle glaucoma (OAG) and age-related macular degeneration (AMD), as shown in a study.

Elevated levels of glycated albumin appear to indicate a greater risk of all-cause and cardiovascular mortality among adults, regardless of their diabetes status, according to a study.

In patients with type 2 diabetes mellitus (DM) or heart failure with preserved ejection fraction (HFpEF), neutrophils seem to secrete more cytokines, contributing to low-grade chronic inflammation, a recent study reports.

In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.

In patients with type 2 diabetes mellitus (T2DM), abdominal aortic calcification might be an important indicator of coronary artery disease (CAD) and cerebral infarction (CI), a new study has found.

The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.

Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.